In a potentially groundbreaking finding, research published this week suggests that GLP-1 receptor agonists — the class of diabetes drugs that includes semaglutide (marketed as Ozempic and Wegovy) — could prevent anxiety and depression from worsening. With Type 2 diabetes affecting more than 800 million people globally, and those with the condition roughly twice as likely to suffer from depression, the implications are enormous. The study’s authors suggest these drugs may prove useful for treating the mental health conditions that so often accompany diabetes — an unexpected benefit from a drug class that has already transformed metabolic medicine.
